Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
Koji Haratani, Kazuhiko Nakagawa(Dana-Farber Cancer Institute), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Ochanomizu University), Yosuke Togashi(Okayama University), Hiroshige Yoshioka(Harbin Medical University), Hidetoshi Hayashi(Kindai University Sakai Hospital), Kimio Yonesaka(Kindai University Hospital), Taro Tanaka(Kurashiki Central Hospital), Kazuya Tanimura(Kishiwada City Hospital), Shuta Tomida(Okayama University), Kenya Hayashi(Nagasaki University), Takayuki Takahama(Kindai University), Junko Tanizaki(Kindai University), Tetsuya Mitsudomi(Kindai University), Hiroyasu Kaneda(Kindai University), Masayuki Takeda(Kindai University), Takeshi Yoshida(Moffitt Cancer Center), Tadashi Ishida(Kurashiki Central Hospital), Yoshikane Nonagase(Kindai University), Kaoru Tanaka(Kindai University), Kazuto Nishio(Kindai University)
Cited by 294
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k